Urothelial Cancer

>

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Latest News

urothelial cancer |   Image Credit: © freshidea - stock.adobe.com
Avelumab Maintenance Proves Equally Effective in Real-World Urothelial Carcinoma Population

March 1st 2024

Frontline maintenance therapy with avelumab following platinum-based chemotherapy led to similar outcomes in routine clinical practice and the JAVELIN Bladder 100 trial in metastatic urothelial cancer.

Ahsan Arozullah, MD, MPH, senior vice president and head of Oncology Development at Astellas
Enfortumab Vedotin Plus Pembrolizumab Receives Priority Review in Japan for First-Line Urothelial Carcinoma

February 16th 2024

Matthew Galsky, MD, professor, medicine, director, genitourinary medical oncology, co-director, the Center of Excellence for Bladder Cancer, associate director, translational research, the Tisch Cancer Institute, Mount Sinai
Enfortumab Vedotin/Pembrolizumab Signals Shift in Urothelial Carcinoma Treatment Paradigm

February 15th 2024

Ahsan Arozullah, MD, MPH, of Astellas
Japanese Approval Sought for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 1st 2024

Roger Dansey, MD
EMA Validates Application for First-Line Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 30th 2024

Video Series
Video Interviews
Podcasts
Terence Friedlander, MD
Latest CME Events & Activities

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

Miami Breast 2024: Affiliated CE Symposia

March 7, 2024 - March 10, 2024

View More

Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK-Targeted Strategies Tell Us?

March 19, 2024

Register Now!

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News